Somewhat Favorable News Coverage Somewhat Unlikely to Impact OraSure Technologies (OSUR) Stock Price

Media coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.5219530694152 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

OraSure Technologies traded up $0.24, hitting $15.85, during midday trading on Wednesday, MarketBeat.com reports. 4,090 shares of the stock were exchanged, compared to its average volume of 642,658. OraSure Technologies has a fifty-two week low of $15.63 and a fifty-two week high of $15.85. The stock has a market cap of $966.64 million, a P/E ratio of 31.06, a PEG ratio of 4.15 and a beta of 1.69.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. OraSure Technologies had a net margin of 9.28% and a return on equity of 6.58%. The business had revenue of $41.99 million during the quarter, compared to analysts’ expectations of $40.53 million. During the same period last year, the business earned $0.21 earnings per share. The business’s revenue for the quarter was up 29.0% on a year-over-year basis. research analysts anticipate that OraSure Technologies will post 0.31 earnings per share for the current fiscal year.

A number of brokerages have issued reports on OSUR. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Friday, May 4th. TheStreet lowered shares of OraSure Technologies from a “b” rating to a “c+” rating in a research note on Wednesday, May 2nd. Zacks Investment Research upgraded shares of OraSure Technologies from a “sell” rating to a “hold” rating and set a $17.00 price objective on the stock in a research note on Wednesday, May 2nd. BidaskClub lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. Finally, Canaccord Genuity restated a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a research report on Friday, February 2nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. OraSure Technologies currently has an average rating of “Hold” and a consensus price target of $20.75.

In other news, Director Stephen S. Phd Tang sold 23,333 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $17.97, for a total transaction of $419,294.01. Following the completion of the sale, the director now owns 59,749 shares in the company, valued at approximately $1,073,689.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Brian Smith sold 20,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares of the company’s stock, valued at approximately $504,507.75. The disclosure for this sale can be found here. 2.90% of the stock is owned by company insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply